Jove
Visualize
联系我们

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
The Sarcomere01:08

The Sarcomere

17.1K
A sarcomere is a microscopic segment repeating in a myofibril. The sarcomere fundamentally consists of two main myofilaments: thick filaments called myosin and thin filaments called actin. These filaments interact by sliding past each other in response to stimulus. In addition to myosin and actin, several other proteins, such as tropomyosin, troponin, titin, nebulin, myomesin, α-actinin, and dystrophin, play crucial roles in regulating, structuring, and functioning of the sarcomere.
Each...
17.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Skin Cancer01:30

Skin Cancer

6.3K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study.

Oncology and therapy·2026
Same author

Response to Letter to the Editor: Comments on "Surgery for Retroperitoneal Soft Tissue is Safe following Multimodal Treatment with Regional Hyperthermia".

Annals of surgical oncology·2026
Same author

Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial.

Cancer·2026
Same author

Initial Clinical Experience with [<sup>177</sup>Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

The New England journal of medicine·2026
Same author

Evaluation of RECIST v1.1 for predicting overall survival in sarcoma patients with pulmonary metastasis.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

[Digital patient journey after radiological diagnostics : Patient portals-what comes after the examination?]

Radiologie (Heidelberg, Germany)·2026
Same journal

[Before the examination: digital check-in].

Radiologie (Heidelberg, Germany)·2026
Same journal

[National infrastructures and the European Health Data Space].

Radiologie (Heidelberg, Germany)·2026
Same journal

[The digital patient journey : Performing radiological examinations].

Radiologie (Heidelberg, Germany)·2026
Same journal

Radiologie (Heidelberg, Germany)·2026
Same journal

Radiologie (Heidelberg, Germany)·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Feb 24, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.4K

[萨尔科马:临床介绍]

Lars H Lindner1

  • 1Zentrum für Knochen- und Weichteiltumoren (SarKUM), LMU Klinikum, Medizinische Klinik III, Marchioninistr. 15, 81377, München, Deutschland. lars.lindner@med.uni-muenchen.de.

Radiologie (Heidelberg, Germany)
|February 23, 2026
PubMed
概括
此摘要是机器生成的。

放射性诊断对于瘤治疗计划至关重要. 精确的成像解释,包括全身MRI,有助于检测转移并评估治疗反应,确保瘤安全,同时尽量减少辐射暴露.

关键词:
多学科的护理服务.新辅助疗法是一种新辅助疗法.伪进步是一种伪进步.肉瘤成像成像研究全身磁共振成像全身磁共振成像

更多相关视频

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

相关实验视频

Last Updated: Feb 24, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.4K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

科学领域:

  • 在瘤学瘤学.
  • 放射学 放射学是一门学科.
  • 医疗成像医学成像

背景情况:

  • 瘤是连接组织的异质恶性瘤.
  • 专门的放射学专业知识对于准确的诊断和治疗计划至关重要.
  • 放射科医生识别可疑的发现,并促进转介到专门的中心.

研究的目的:

  • 突出放射性诊断在肉瘤管理中的关键作用.
  • 强调需要根据肉瘤亚型量身定制的成像策略.
  • 解决评估治疗反应和随访期间的挑战.

主要方法:

  • 对各种类型的肉瘤亚型的成像策略的审查.
  • 讨论全身MRI用于检测骨转移 (例如,myxoid liposarcoma).
  • 分析在新辅助环境中将伪进展与真正进展区分开来所面临的挑战.

主要成果:

  • 准确的成像解释是瘤治疗计划的第一步.
  • 定制成像策略,如全身MRI,对于特定的亚型是必不可少的.
  • 区分与治疗相关的变化和瘤进展是一个关键的挑战.

结论:

  • 放射科医生是早期检测,转诊和治疗瘤治疗计划的核心.
  • 适当的成像策略取决于亚型,对于有效管理至关重要.
  • 在肉瘤的随访中,平衡瘤安全与辐射暴露至关重要.